Diana Ernst, RPh

An FDA panel has voted in favor of the safety and effectiveness of Paxlovid for COVID-19.

This age group is now eligible to receive the booster dose at least 2 months after they complete primary vaccination with 3 doses of the monovalent vaccine.

Results showed a significantly greater proportion of patients treated with tapinarof cream achieved vIGA-AD success compared with vehicle cream.

The approval was supported by data from the randomized, double-blind, placebo-controlled phase 3 LAVENDER study.

Earlier this month, Global Pharma Healthcare had announced a nationwide recall of its artificial tear lubricant eye drops distributed by EzriCare, LLC and Delsam Pharma.

Tepezza, a fully human monoclonal antibody, is approved for the treatment of thyroid eye disease.

The BLA submission is based on positive results across four phase 3 studies in wet AMD and DME.